In-vitro and in-vivo anti-inflammatory action of the ethanol extract of Trachelospermi caulis.
In this study, we aimed to investigate the anti-inflammatory activity, antinociceptive activity and the action mechanism of Trachelospermi caulis extract. The anti-inflammatory effects were investigated using arachidonic acid, 12-O-tetradecanoylphorbol 13-acetate or carrageenan-induced oedema assays. Antinociceptive activity, using the acetic acid-induced writhing model, was also tested in mice. The extract exhibited dose-dependent and significant (P<0.05 at 100-400 mg kg-1) anti-inflammatory and antinociceptive activity in the animals. To further understand the mechanism of activity, we investigated whether the extract inhibited the expression of inducible nitric oxide synthase (iNOS), the production of nitric oxide (NO) and the expression of TNF-alpha from murine macrophage RAW 264.7 cells. Similar to the in-vivo activity, the iNOS expression, NO production and TNF-alpha expression were found to be dose dependent and significantly suppressed by the extract through the inhibition of the p38 MAP kinase/NF-kappaB pathway. Taken together, the results presented here suggest that T. caulis extract may be useful for the treatment of various inflammatory diseases.
Lee
Mu Hong
MH
Life Science R&D Center, Sinil Pharmaceutical Co., Ltd., Chungju 380-862, Korea.
Lee
Jeong Min
JM
Jun
Sung Hoon
SH
Ha
Chul Gyu
CG
Lee
Seung-Ha
SH
Kim
Nam Wook
NW
Lee
Jun Ho
JH
Ko
Na Young
NY
Mun
Se Hwan
SH
Park
Seung Hwa
SH
Kim
Bo Kyung
BK
Her
Erk
E
Kim
Young Mi
YM
Choi
Wahn Soo
WS
D019342:Acetic Acid; D000700:Analgesics / Q000494:pharmacology*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D016718:Arachidonic Acid; D002351:Carrageenan; D002460:Cell Line; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy*; D000431:Ethanol / Q000737:chemistry; D005663:Furans / Q000032:analysis; D005960:Glucosides / Q000032:analysis; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009569:Nitric Oxide / Q000096:biosynthesis; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D010146:Pain / Q000139:chemically induced / Q000188:drug therapy*; D010936:Plant Extracts / Q000032:analysis / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013755:Tetradecanoylphorbol Acetate; D051996:Transcription Factor RelA / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D048051:p38 Mitogen-Activated Protein Kinases / Q000378:metabolism
D000700:Analgesics; D000893:Anti-Inflammatory Agents; D005663:Furans; D005960:Glucosides; D010936:Plant Extracts; D051996:Transcription Factor RelA; D014409:Tumor Necrosis Factor-alpha; D016718:Arachidonic Acid; D009569:Nitric Oxide; D000431:Ethanol; D002351:Carrageenan; D052247:Nitric Oxide Synthase Type II; D048051:p38 Mitogen-Activated Protein Kinases; D013755:Tetradecanoylphorbol Acetate; D019342:Acetic Acid; C077992:arctiin